Viral bronchiolitis is the most common cause of hospitalization among infants. Despite its prevalence, no consistently effective therapy has been found to date, providing the driving force behind much of the ongoing research into this illness. In this review, we present a summary of the most recent published trials of interventions for bronchiolitis. Included are studies evaluating bronchodilators, corticosteroids, positive pressure ventilation, as well as 3 newer therapies for bronchiolitis: heliox, mucolytics, and leukotriene receptor antagonists.
Clinical Instructor (Petruzella), Professor (Gorelick), Division of Emergency Medicine, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI.
Reprints: Frank D. Petruzella, MD, Medical College of Wisconsin, Children's Corporate Center, Suite 550, 999 N 92nd St, Milwaukee, WI 53226 (e-mail: email@example.com).
Dr. Gorelick has disclosed that he received research grant support from Merck & Co., and Dr. Petruzella has disclosed that he has no financial relationships with, or financial interests in any commercial companies pertaining to this educational activity.
The authors have disclosed that the use of albuterol, ipatropium, epinephrine, dexamethasone, prednisolone, deoxyribonuclease, and montelukast for treatment of viral bronchiolitis as discussed in this article has not been approved by the U.S. Food and Drug Administration.
Unless otherwise noted, the staff's and faculty's spouse/life partner (if any) has nothing to disclose.
The authors and all staff in a position to control the content of this CME activity have disclosed that they have no financial relationships with, orfinancial interests in, any commercial companies pertaining to this educational activity